Libtayo® (cemiplimab) receives positive chmp opinion recommending approval to treat advanced cervical cancer

Recommendation based on a phase 3 libtayo trial that was first and only to demonstrate significantly improved survival compared to chemotherapy in the second-line setting irrespective of pd-l1 expression status or tumor histology tarrytown, n.y. , oct. 14, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted a positive opinion for libtayo® (cemiplimab) as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
REGN Ratings Summary
REGN Quant Ranking